Fulcrum Therapeutics (FULC) Non-Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Non-Current Assets data on file, last reported at $8.1 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 19.74% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $35.4 million, a 23.74% decrease from a year earlier, with the FY2025 full-year figure at $8.8 million, down 18.44% from the prior year.
• Non-Current Assets for Q1 2026 stood at $8.1 million, down from $8.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for FULC reached as high as $21.0 million in Q2 2022 and fell as low as $8.1 million in Q1 2026.
• Historically, Non-Current Assets has averaged $14.4 million across 5 years, with a median of $14.6 million in 2024.
• Across the five-year window, Non-Current Assets jumped 124.02% in 2022 and tumbled 32.25% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $19.2 million in 2022, then dropped by 19.15% to $15.5 million in 2023, then tumbled by 30.33% to $10.8 million in 2024, then dropped by 18.44% to $8.8 million in 2025, then declined by 7.99% to $8.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $8.1 million in Q1 2026, $8.8 million in Q4 2025, and $9.0 million in Q3 2025.